News

Chris Brittain, vice president, Global Head of Ophthalmology Product Development at Genentech, sat with Ophthalmology Times to discuss the company's plans with Susvimo following the FDA approval for relaunch.

GLP-1 receptor agonists, such as Wegovy, Ozempic and Novo Nordisk, are becoming more prolific

The company announced it has received FDA approval to relaunch Susvimo for intravitreal use via an ocular implant for treating people with wet AMD.

The company has secured $170 million (approximately €157 million) in Series B funding

NVK002 atropine 0.01% (Vyluma Inc.) “meaningfully slowed” myopia progression in myopic pediatric patients over a 36-month period.

Most respondents were unsure of how to seek treatment and see dry eye as something that must be learned to live with.

The company states this will enable movement toward US approval

The funding will go toward the continued clinical development of the company’s lead asset, AGTC-501 (laruparetigene zovaparvovec)

Technology offers increased usability, safety, and accuracy in MIGS procedures.

Ella Faktorovich, MD, sat with Ophthalmology Times to discuss an anti-inflammatory treatment protocol she has been using to treat recurrent erosions after corneal refractive surgery.

The pharmaceutical candidate is being evaluated as a potential treat for nAMD.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss a unique case of a 15-year-old who showed signs of meningioma with epithelial whirls and some psammoma bodies in the eye.

IKA Keratoconus Symposium and Controversies in Modern Eye Care shone brightly in May

42nd Annual Meeting in Stockholm, the Venice of the North

Comanagement is a key component for treatment of disease.

According to Genentech, faricimab-svoa is the first and only syringe prefilled with an FDA-approved bispecific antibody for the treatment of wet AMD, DME and RVO.

According to Genentech, faricimab-svoa is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness.

The SimVis Gekko eye dominance strength test may change the standard of care.

Patients with corneal astigmatism underwent phacoemulsification and rotationally asymmetric multifocal IOL implantation

Durga Borkar, MD, MMCi, recently discussed the quality data (Qdata, Verana Health) gathered on geographic atrophy as well as the GATHER 1 and GATHER 2 data.

Educational resources include handouts, videos and a dedicated webpage on the proper way to use eye drops

The deal included a total upfront consideration of $81 million, including a cash payment of approximately $65 million.

Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular edema.

Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea

The company expects approval from the EMA by 2025.

From amniotic membrane grafting to neurotization.

Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular oedema